Omeros Corporation (NASDAQ: OMER) saw its shares plunge approximately 50% on Friday after the European Medicines Agency’s (EMA) expert panel issued a negative opinion on the marketing authorization application for narsoplimab, marketed as Yartemlea in the United States. The decision, which caught many investors off guard, stems from concerns over the drug’s clinical trial design and data architecture.
The EMA panel specifically flagged that the primary study for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) enrolled only 28 adults without a randomized, placebo-controlled baseline. This lack of comparative data undermined confidence in the monoclonal antibody’s absolute efficacy, leading to a flat refusal to endorse the therapy for European commercial distribution.
European Setback vs. US Momentum
While the European rejection is a clear blow to Omeros’ international expansion plans, the company’s domestic commercial engine remains robust. Yartemlea generated $9.9 million in net sales during the first quarter of 2026, far exceeding consensus expectations of $4.1 million. This strong performance underscores the drug’s established foothold in the US market.
Furthermore, a significant catalyst is imminent: the US Centers for Medicare & Medicaid Services (CMS) has finalized a permanent, product-specific reimbursement J-code (J1289) for Yartemlea, effective July 1, 2026. This code streamlines institutional billing and accelerates insurance reimbursements, which should boost US demand and visibility. As noted in our coverage of Moderna’s recent regulatory win, clear reimbursement pathways often drive near-term ordering behavior.
Appeal Process and Key Risks
Omeros management has announced plans to appeal the EMA decision and request a detailed re-examination via an Ad Hoc Expert Group (AHEG). However, appeals within the EMA framework are notoriously protracted, and reversals of initial negative opinions are statistically rare. This introduces months of uncertainty, effectively making Europe a “dead-money” overhang for the stock.
Key risks include the possibility that the appeal fails, hardening the EMA’s negative stance and potentially damaging US uptake through loss of confidence or physician pullback. Additionally, the J-code catalyst may not translate into faster real-world prescribing if coverage limits or prior authorization friction persist.
Is Omeros a Buy-the-Dip Opportunity?
For investors focused on the US market, the fundamentals remain intact. The strong Q1 sales and upcoming J-code upgrade suggest that Yartemlea’s domestic revenue trajectory is solid. The J-code also signals that payers and regulators are comfortable with the drug’s value, which could lift sentiment across the transplant complications treatment ecosystem.
However, the European setback has slashed near-term ex-US revenue forecasts, and the stock’s forward valuation now hinges heavily on US execution. As highlighted in our analysis of AI trade volatility, sharp drawdowns in high-conviction biotech names often create entry points for disciplined investors—but only if the core thesis remains unbroken.
In Omeros’ case, the US commercial engine is firing on all cylinders, and the J-code catalyst is a tangible near-term driver. The European appeal is a long shot, but the domestic opportunity alone may justify a selective, risk-managed position for those willing to tolerate the regulatory overhang.
This article is for informational purposes only and does not constitute financial advice.
